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Special oncology diagnostics require new types of selective radiopharmaceuticals, especially those that are 
suitable for molecular PET imaging and therapy, respectively, teranostics. The aim of this work is to present 
a new target radiopharmaceutical for immunoPET diagnosis and therapy based on the monoclonal antibody 
IgG M75 directed to human carbonic anhydrase IX, nimotuzumab (hR3) target epidermal growth factor 
receptor (EGFR) and one of the bombesin derivatives (BBN) repeats. These molecules were labeled with 
radionuclides 64Cu (t1/2 12.70 hours), 61Cu (t1/2 3.33 hours), 68Ga (t1/2 68 min), 177Lu (t1/2 6.71 days). 
These potential radiopharmaceuticals were evaluated in vitro and in vivo. The IgG M75 antibody and its 
scFv-Fc M75 fragment were prepared by the genetic modification were conjugated to a specific chelator 
specific phosphinate (PHS) and radiolabeled by the radionuclides 61,64Cu. The stability of the labeled 
conjugate was tested in human serum. Immunoreactivity of the labeled conjugate was evaluated in vitro on 
suitable colorectal carcinoma (HT-29) cell cultures and its imaging properties were estimated from in vivo 
and in vitro by HT-29 carcinoma experiments imaged by μPET/CT. The immunoconjugate was obtained at a 
specific activity of 0.7 to 0.1 MBq/μg. In vitro binding experiments revealed specific binding to HT-29 cells (45 
± 2.8 % of total activity added) and KD values measured at 9.2 nM. Imaging unambiguously demonstrated a 
significant distribution of labeled monoclonal antibodies in the tumor 18 hours after administration. The 
radioimmunoconjugate IgG M75-NCS-PHS-Cu-64 seems to be a suitable candidate for PET diagnosis of 
hypoxic tumors expressing human carbohydrate IX. hR3 was further conjugated to commercial DOTA 
chelator and unconventional chelator DOTAPO, these conjugates were labeled with radionuclides 64Cu and 
177Lu with specific activities of 0.2 and 0.5 MBq/μg and subsequently evaluated in vitro on A431 cell 
cultures including in vivo imaging experiments on µSPECT/CT. The BBN peptide was conjugated with the 
DOTA chelator and labeled with 64Cu and 68Ga radionuclides with specific activities of 10 and 0.1 MBq/μg. 
Labeled conjugates were evaluated in vitro on PC-3 cell line models and imaged in vivo on μPET/CT. 
